Pricing Log in Create free account

GRAIL, Inc. (GRAL) vs NeoGenomics, Inc. (NEO)

GRAIL, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.3B against $2.1B — 2.5× the size. GRAIL, Inc. grew revenue faster over the last twelve months: 17.5% against 11.1%. NeoGenomics, Inc. has the higher net margin (−4.10% vs −243.8%) and the higher return on invested capital (−2.97% vs −14.7%). Across the 17 metrics below, NeoGenomics, Inc. leads on 12 and GRAIL, Inc. on 5.

Valuation

Metric GRAL NEO Diagnostics & Research median
P/E n/m n/m 35.23
P/S 33.96 2.76 4.08
P/B 2.31 2.71 3.45
Price to free cash flow n/m n/m 33.72
EV/EBITDA n/m 149.24 25.01
EV/Sales 28.79 3.32 5.20
Earnings yield (7.86%) (1.47%) (1.47%)
Free cash flow yield (5.52%) (1.22%) 0.00%

Profitability

Metric GRAL NEO Diagnostics & Research median
Gross margin 0.00% 44.77% 48.32%
Operating margin (347.28%) (6.27%) (5.68%)
Net margin (243.80%) (4.10%) (4.10%)
Free cash flow margin (187.27%) (3.37%) 0.00%
Return on equity (17.31%) (3.94%) 0.00%
Return on assets (15.24%) (2.35%) (6.05%)
Return on invested capital (14.74%) (2.97%) 0.00%

Growth

Metric GRAL NEO Diagnostics & Research median
Revenue growth (TTM) 17.47% 11.08% 9.15%
EPS growth (last fiscal year) 82.51% (35.48%) 20.36%
Revenue growth, 5-year CAGR — 10.35% 7.30%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric GRAL NEO Diagnostics & Research median
Debt to equity 0.00 0.47 0.04
Current ratio 8.93 3.53 2.27
Net debt to EBITDA 2.27 (3.96) 0.68

Dividend

Metric GRAL NEO Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric GRAL NEO Diagnostics & Research median
Market cap 5.32b 2.13b 1.93b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack